IVF for Genetic Disease Carriers in Thailand: PGT-M Technology to Block Disease Transmission
Beginning: Real consultation scenario
A woman carrying the β-thalassemia gene, whose spouse was confirmed to be a carrier of the same type of thalassemia gene after screening. Both partners are asymptomatic carriers, but there is a 25% chance that a naturally conceived fetus will inherit severe thalassemia. After experiencing a prenatal diagnosis confirming severe thalassemia and terminating the pregnancy, she consulted online: "My husband and I are both thalassemia carriers. If we go to Thailand for IVF, can we screen out embryos that do not carry the pathogenic gene at all?" This is a typical issue faced by genetic disease carriers in their reproductive decisions and the core question this article aims to answer.
Can genetic disease carriers undergo IVF in Thailand? A direct answer
Yes. Genetic disease carriers can undergo IVF in Thailand. The core is the use of Preimplantation Genetic Testing for Monogenic Diseases (PGT-M) technology to screen for healthy embryos that do not carry the specific pathogenic gene before embryo transfer. Some fertility centers in Thailand have the capability to perform PGT-M, enabling precise detection of known pathogenic genes. This technology is applicable to various inheritance patterns, including autosomal dominant, autosomal recessive, and X-linked genetic disorders.
Applicable conditions include:
- Pathogenic gene locus identified through genetic testing (requires a formal genetic test report)
- Both partners have completed genetic verification, confirming the same mutation site
- The chosen fertility center has experience in monogenic disease testing or collaborates with a genetic laboratory
- The female's ovarian function can support obtaining a sufficient number of eggs to ensure enough embryos for testing
Non-applicable situations:
- Genetic diseases with unidentified pathogenic gene loci (cannot design detection probes)
- Genetic diseases involving multiple genes or unknown gene mutations
- Severely diminished ovarian function in the female, with a very low expected egg count (e.g., AMH below 0.5 ng/mL and antral follicle count less than 3)
Why genetic disease carriers need PGT-M technology
Genetic disease carriers themselves usually do not show symptoms or have only mild symptoms, but they can pass the pathogenic gene to their offspring. For example, in autosomal recessive genetic diseases, when both partners are carriers of the same type, there is a 25% chance the offspring will be affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being completely healthy. Traditional prenatal diagnosis (amniocentesis, chorionic villus sampling) can only confirm whether the fetus is affected after pregnancy. If a severe genetic disease is diagnosed, the decision to terminate the pregnancy must be faced, causing significant physical and psychological trauma to the mother.
PGT-M technology advances genetic testing to the embryo stage, screening for completely healthy embryos before transfer, thereby blocking the transmission of genetic diseases at the source and avoiding the risk of discovering fetal abnormalities after pregnancy. This technology is currently the most effective means of blocking known pathogenic gene genetic diseases.
Professional perspective from reproductive medicine: How doctors view it
From a reproductive medicine perspective, the core aspect of IVF for genetic disease carriers is genetic testing, requiring close collaboration between reproductive medicine and genetics departments. A complete PGT-M cycle involves three key roles:
- Reproductive doctor: Responsible for ovarian stimulation protocol, egg retrieval surgery, embryo culture, and transfer
- Genetic counselor: Assesses genetic risk, interprets genetic reports, and communicates embryo test results
- Genetic laboratory: Performs embryo biopsy and genetic testing, issuing test reports
In practice, doctors focus on: the timing of embryo biopsy (usually at the blastocyst stage on days 5-6), the number of biopsied cells (5-10 trophectoderm cells), and the choice of testing platform (NGS or qPCR). Patients must also be informed that due to the time required for testing, all embryos need to be frozen, and transfer will be scheduled after the test results are available.
Policy differences for genetic disease IVF across countries
When genetic disease carriers choose overseas IVF, they need to consider the regulatory restrictions on PGT in different countries. Below is a comparison of several major countries:
| Country | PGT-M Policy | Restrictions for Genetic Disease Carriers | Reference Cost (RMB) |
|---|---|---|---|
| Thailand | Allowed | Requires genetic disease diagnosis certificate and genetic report; non-medical sex selection is prohibited | 120,000 - 180,000 (including PGT-M) |
| China | Allowed (with indications) | Must meet national genetic disease indications; strict approval process | 80,000 - 120,000 (including PGT-M) |
| United States | Allowed | Well-established laws, mature technology, but higher cost | 250,000 - 400,000 (including PGT-M) |
| Cambodia | Allowed | Relatively relaxed regulations, but limited medical resources and laboratory conditions | 100,000 - 150,000 (including PGT-M) |
Thailand occupies a middle ground in terms of policy flexibility and medical resources. It lacks the strict approval restrictions of China and is not as expensive as the United States, making it a popular choice for many genetic disease carriers. However, it is important to note that the experience of different fertility centers with PGT-M varies significantly, and their genetic laboratory qualifications and past case numbers should be verified when choosing.
Actual process: Complete steps for genetic disease carriers undergoing IVF in Thailand
A complete PGT-M cycle is divided into the following stages, with a total duration of about 3-4 months:
Stage 1: Genetic counseling and gene verification (about 1-2 months)
- Both partners submit existing genetic test reports or undergo whole exome sequencing to confirm the pathogenic gene locus
- The genetic counselor assesses the inheritance pattern and calculates the risk of disease in offspring
- Design of monogenic disease detection probes (takes 4-8 weeks), a key preparatory step for PGT-M
Stage 2: IVF cycle (about 2-3 weeks)
- The female undergoes ovarian stimulation (about 10-12 days) with regular monitoring of follicle development
- Egg retrieval surgery (about 30 minutes, under intravenous sedation)
- Fertilization of eggs with sperm (ICSI)
- Embryo culture to the blastocyst stage on days 5-6
Stage 3: Embryo biopsy and genetic testing (about 2-4 weeks)
- Trophectoderm biopsy of the blastocyst (taking 5-10 cells)
- Embryo cryopreservation (vitrification)
- Biopsied cells sent to the genetic laboratory for genetic testing (NGS platform)
- Issuance of the embryo genetic test report, clarifying the genetic status of each embryo
Stage 4: Embryo transfer (1 day)
- Selection of healthy embryos not carrying the pathogenic gene based on test results
- Endometrial preparation for the female (natural cycle or hormone replacement cycle)
- Thawing and transfer of the embryo (about 5 minutes, no anesthesia required)
- Blood test for pregnancy 12-14 days after transfer
Easily overlooked detail: Gene verification requires both partners to complete it simultaneously
A common misconception is that a genetic disease carrier can go directly to Thailand for PGT-M after having their own genetic test. In reality, both partners must complete genetic verification simultaneously, because:
- For recessive genetic diseases, it is necessary to confirm whether both partners carry the same pathogenic mutation
- For dominant genetic diseases, it is necessary to confirm whether the spouse also carries the mutation or has a de novo mutation
- Probe design requires DNA samples from both partners for site confirmation
If only one partner has completed testing, the genetic laboratory cannot design a specific probe for that family, and PGT-M cannot proceed. Therefore, couples planning to go to Thailand for genetic disease IVF should complete genetic testing for both partners simultaneously in advance to avoid wasting time.
Cost factors: Why PGT-M is more expensive than standard IVF
The cost of IVF for genetic disease carriers is significantly higher than standard IVF, mainly due to the following additional components:
| Cost Item | Standard IVF | PGT-M IVF | Reason for Difference |
|---|---|---|---|
| Genetic counseling and genetic testing | None | Approx. 10,000 - 30,000 RMB | Requires whole exome sequencing, probe design, genetic counseling fees |
| Embryo biopsy fee | None | Approx. 20,000 - 40,000 RMB | Requires micromanipulation equipment and embryologist expertise |
| Genetic testing fee (embryo) | None | Approx. 20,000 - 50,000 RMB | Charged per embryo, about 3,000 - 8,000 RMB per embryo |
| Embryo freezing fee | Approx. 10,000 - 20,000 RMB | Approx. 10,000 - 20,000 RMB | All embryos must be frozen while waiting for test results |
| Basic IVF costs | Approx. 80,000 - 120,000 RMB | Approx. 80,000 - 120,000 RMB | Ovarian stimulation, egg retrieval, culture, transfer, etc. |
Overall, the cost of PGT-M IVF in Thailand is about 50,000 - 80,000 RMB higher than standard IVF, with a total cost ranging from 120,000 to 180,000 RMB. The exact amount is influenced by factors such as the number of embryos, the testing platform, and hospital pricing.
Handling special cases: When genetic conditions are complex
Not all genetic disease carriers are suitable for directly entering the PGT-M process. The following special situations require additional evaluation:
- De novo mutations: If the patient's pathogenic gene is a de novo mutation (neither parent carries it), the source of the mutation needs to be confirmed, and probe design is more complex
- Mosaic mutations: Some patients are mosaics, with different genotypes in different tissue cells, requiring verification through sperm or eggs
- Mitochondrial genetic diseases: Mitochondrial diseases cannot be completely blocked by PGT-M; mitochondrial replacement therapy (MRT) may be considered, but it is not yet available in Thailand
- X-linked genetic diseases: Female carriers have a 50% chance of passing the pathogenic gene to their sons (who will be affected). This can be managed through sex selection combined with PGT-M, but must meet medical indications
For complex genetic diseases, it is recommended to first complete a detailed genetic consultation domestically to determine whether PGT-M is suitable before deciding to go to Thailand. Starting an IVF cycle blindly may carry the risk of being unable to complete the testing.
How to determine if you are suitable for genetic disease IVF in Thailand
The following criteria can serve as a reference:
- Pathogenic gene locus identified through formal genetic testing (with a genetic test report)
- Both partners are willing to cooperate with genetic verification and genetic counseling
- Female age under 40, AMH ≥ 1.0 ng/mL, antral follicle count ≥ 6
- No severe uterine pathologies (e.g., intrauterine adhesions, adenomyosis)
- Able to accept the arrangement of embryo freezing and delayed transfer
- Has reasonable expectations regarding the limitations and residual risks of PGT-M testing
Situations requiring careful evaluation:
- Female age over 42 with significantly diminished ovarian function
- Genetic disease with unidentified pathogenic gene locus
- Presence of multiple genetic diseases or complex chromosomal abnormalities
- Unable to accept the outcome of having no transferable embryos after testing
Preparations needed before IVF in Thailand
If you decide to go to Thailand for PGT-M IVF, it is recommended to make the following preparations in advance:
- Genetic documentation: Organize complete genetic test reports, genetic counseling records, and family medical history, and have them translated into English
- Medical examinations: Both partners complete pre-operative tests, including infectious disease screening, semen analysis, AMH, sex hormone panel, thyroid function, etc.
- Time planning: From the initial consultation to the completion of transfer, it is recommended to allow at least 4 months; probe preparation takes 1-2 months and should be arranged in advance
- Document preparation: Passport must be valid for at least 6 months, marriage certificate with translation and notarization (required by some hospitals)
- Financial preparation: Budget 120,000 - 180,000 RMB, with an additional 20,000 - 30,000 RMB as a reserve
Common questions and clarification of misconceptions
Q: After PGT-M testing, is the embryo guaranteed to be completely healthy?
A: PGT-M only tests for the specific known pathogenic gene and does not screen for other genetic or chromosomal abnormalities. The embryo may have other unknown genetic issues, so PGT-M cannot guarantee 100% health, but it ensures the target genetic disease is blocked.
Q: Can all fertility centers in Thailand perform PGT-M?
A: No. Only centers with a genetic laboratory or collaboration with a professional genetic institution can offer it. When choosing, it is necessary to verify the center's experience and qualifications in monogenic disease testing.
Q: How far in advance should I prepare for IVF in Thailand?
A: At least 2-3 months in advance. The main time consumption is in the gene verification and probe preparation stages (1-2 months). It is recommended to complete these steps before arranging travel.
Q: Can older (over 40) genetic disease carriers undergo the procedure?
A: Yes, but ovarian function needs to be assessed. Older women may have fewer eggs retrieved, and a lower number of embryos increases the risk of having no transferable embryos. It is recommended to first have an AMH test and antral follicle count evaluation.
Risk reminders
Genetic disease carriers undergoing PGT-M IVF in Thailand need to be fully aware of the following risks:
- Risk of no transferable embryos: Due to genetic screening eliminating some embryos, combined with the natural attrition rate of IVF, there may ultimately be no completely healthy embryos available for transfer. This risk increases with age.
- Risk of testing error: The number of biopsied embryo cells is limited, and there is a possibility of amplification failure or allele drop-out (ADO), leading to inaccurate test results. Reputable laboratories control the error rate to below 1%.
- Residual risk: PGT-M cannot completely rule out the risk of mosaicism or de novo mutations. Prenatal diagnosis is still recommended after transfer for confirmation.
- Cross-border medical risks: There are uncertainties regarding language communication, legal rights protection, and medical dispute resolution. It is advisable to choose a qualified medical coordination organization (not an agency) for support.
- Financial risk: If the cycle is cancelled due to insufficient embryos or testing failure, the costs incurred are non-refundable. Financial preparation should be made in advance.
It is recommended that all genetic disease carriers complete a full genetic consultation domestically before making a decision, to clarify whether their genetic disease is suitable for PGT-M and whether it is necessary to go abroad. Cross-border medical treatment is a means, not an end. The core goal is to have healthy children in the safest and most effective way.
